{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:25:39Z","timestamp":1792844739034,"version":"4.5.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1681\/asn.2012020181","type":"journal-article","created":{"date-parts":[[2012,7,20]],"date-time":"2012-07-20T10:11:43Z","timestamp":1342779103000},"page":"1416-1425","source":"Crossref","is-referenced-by-count":288,"title":["Rituximab in Idiopathic Membranous Nephropathy"],"prefix":"10.1681","volume":"23","author":[{"given":"Piero","family":"Ruggenenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cravedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Chianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Gaspari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Maras\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20230208","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/0003-4819-116-8-672","article-title":"NIH conference. Membranous nephropathy.","volume":"116","author":"Austin","year":"1992","journal-title":"Ann Intern Med"},{"key":"R2-20-20230208","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy.","volume":"329","author":"Schieppati","year":"1993","journal-title":"N Engl J Med"},{"key":"R3-20-20230208","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy.","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R4-20-20230208","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1517\/14656566.8.18.3159","article-title":"Latest treatment strategies for membranous nephropathy.","volume":"8","author":"Ruggenenti","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"R5-20-20230208","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.","volume":"18","author":"Jha","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R6-20-20230208","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"key":"R7-20-20230208","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2215\/CJN.11001210","article-title":"Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy.","volume":"6","author":"Cattran","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R8-20-20230208","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1093\/ndt\/gfn350","article-title":"Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: A nationwide survey in the Netherlands.","volume":"23","author":"Hofstra","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R9-20-20230208","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/ndt\/gfr220","article-title":"Idiopathic membranous nephropathy and nephrotic syndrome: Outcome in the era of evidence-based therapy.","volume":"27","author":"McQuarrie","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R10-20-20230208","first-page":"499","article-title":"Management of the nephrotic syndrome in adults","volume":"8","author":"Lewis","year":"1988"},{"key":"R11-20-20230208","first-page":"100","article-title":"Malignancies in Wegener\u2019s granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.","volume":"35","author":"Faurschou","year":"2008","journal-title":"J Rheumatol"},{"key":"R12-20-20230208","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: An analysis of 158 patients.","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"R13-20-20230208","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1053\/ajkd.2002.29926","article-title":"Malignancy after renal transplantation.","volume":"39","author":"Zeier","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R14-20-20230208","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.coi.2008.05.011","article-title":"Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.","volume":"20","author":"Taylor","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"R15-20-20230208","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy.","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"R16-20-20230208","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1097\/01.ASN.0000071511.35221.B3","article-title":"Rituximab in idiopathic membranous nephropathy: A one-year prospective study.","volume":"14","author":"Ruggenenti","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R17-20-20230208","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: A 2-year study.","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R18-20-20230208","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy.","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"key":"R19-20-20230208","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM198404123101503","article-title":"Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy.","volume":"310","author":"Ponticelli","year":"1984","journal-title":"N Engl J Med"},{"key":"R20-20-20230208","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial.","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int"},{"key":"R21-20-20230208","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0272-6386(04)00809-1","article-title":"Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review.","volume":"44","author":"Perna","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R22-20-20230208","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJM199307083290211","article-title":"Idiopathic membranous nephropathy\u2014to treat or not to treat?","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"R23-20-20230208","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"R24-20-20230208","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM199208273270904","article-title":"Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy.","volume":"327","author":"Ponticelli","year":"1992","journal-title":"N Engl J Med"},{"key":"R25-20-20230208","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections.","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin Hematol"},{"key":"R26-20-20230208","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1741-7015-9-36","article-title":"Risk of infection in patients with lymphoma receiving rituximab: Systematic review and meta-analysis.","volume":"9","author":"Lanini","year":"2011","journal-title":"BMC Med"},{"key":"R27-20-20230208","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: Clinical features and pathogenesis.","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"key":"R28-20-20230208","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics, 2006.","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"R29-20-20230208","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2215\/CJN.05231008","article-title":"Rituximab therapy for membranous nephropathy: A systematic review.","volume":"4","author":"Bomback","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R30-20-20230208","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1517\/14740330902750114","article-title":"Ten years of rituximab in NHL.","volume":"8","author":"Winter","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"R31-20-20230208","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: Meta-analyses of randomised placebo-controlled trials.","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R32-20-20230208","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: Experience from a national registry (GRAID).","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R33-20-20230208","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases.","volume":"9","author":"G\u00fcrcan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"R34-20-20230208","first-page":"S96","article-title":"Pathogenetic concepts of membranous glomerulopathy (MGN).","volume":"13","author":"Kerjaschki","year":"2000","journal-title":"J Nephrol"},{"key":"R35-20-20230208","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies.","volume":"346","author":"Debiec","year":"2002","journal-title":"N Engl J Med"},{"key":"R36-20-20230208","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"R37-20-20230208","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R38-20-20230208","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1681\/ASN.2011060610","article-title":"Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy.","volume":"22","author":"Cravedi","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R39-20-20230208","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1681\/ASN.V92310","article-title":"Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease.","volume":"9","author":"Gaspari","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"R40-20-20230208","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.2215\/CJN.01730408","article-title":"Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy.","volume":"3","author":"Ruggenenti","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R41-20-20230208","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1172\/JCI27699","article-title":"Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes.","volume":"116","author":"Remuzzi","year":"2006","journal-title":"J Clin Invest"},{"key":"R42-20-20230208","first-page":"11A","article-title":"The UK Randomised Controlled Trial of Immunosuppression for Progressive Membranous Nephropathy [Abstract].","volume":"22","author":"Mathieson","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R43-20-20230208","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy.","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R44-20-20230208","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.2007090970","article-title":"Role of remission clinics in the longitudinal treatment of CKD.","volume":"19","author":"Ruggenenti","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R45-20-20230208","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s002770100346","article-title":"Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: Case report.","volume":"80","author":"Ng","year":"2001","journal-title":"Ann Hematol"},{"key":"R46-20-20230208","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: Definition and relevance of a partial remission.","volume":"66","author":"Troyanov","year":"2004","journal-title":"Kidney Int"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201208000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:21:55Z","timestamp":1786130515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201208000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2012020181","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717956169.793461037","asserted-by":"object"}]},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}